Development of liposomal polyene antibiotics: An historical perspective

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 6, Issue 1, 2003, Pages 67-83

  Ng, Agatha W K ^a   Wasan, Kishor M ^a   Lopez Berestein, Gabriel ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CDRIL 312; FLUCONAZOLE; HA 1 92; HAMYCIN; INTRALIPID; ITRACONAZOLE; LIPOSOME; MACROLIDE; MEGLUMINE ANTIMONATE; NYSTATIN; POLYENE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOTOXICITY; CELL MEMBRANE; CELL VIABILITY; CHANNEL GATING; CHILL; DIABETES MELLITUS; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG STRUCTURE; ELECTROLYTE TRANSPORT; FEVER; HUMAN; HYPOKALEMIA; LUNG TOXICITY; MAMMAL CELL; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; SCLEROSIS; VEIN DISEASE; VOMITING;

ADENOSINE TRIPHOSPHATE; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CHOLESTEROL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LIPOSOMES; NYSTATIN; POLYENES;

EID: 0037711378     PISSN: 14821826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. E. J. Anaissie, Opportunistic mycoses in the immunocompromised host: experience at cancer center and review, Clin. Infect. Dis. 14(suppl.1), 43-53 (1992).
2. M. A. Pfaller, R. Webzel, The impact of changing epidemiology of fungal infections in the 1990s. Eur. J. Clin. Microbiol. Infect. Dis. 11, 287-291 (1992).
3. M. D. Richardson, Opportunistic and pathogenic fungi, J Antimicrobial. Chemother. 28(suppl. A), 1-11 (1991).
4. T. J. Walsh, Invasive fungal infections: problems and challenges in developing new antifungal compounds in "Emerging Targets in Antibacterial and Antifungal" (J. Sutcliffe and N.H. Georgopapadakou, ed.), p. 249-373. Chapman & Hall, New York, 1992.
5. C. M. Beck-Sague, W. R. Jarvis, Secular trends in the epidemiology of nosocomial fungal infections in the United States, J. Infect. Dis. 167, 1247-51 (1993).
6. D. W. Denning, Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host, J. Antimicrob. Chemother. 28(suppl. B), 1-6 (1991).
7. R. D. Diamond, The growing problem of mycoses in patients infected with the human immunodeficiency virus, Rev. Infect. Dis. 13, 480-6 (1991).
8. G. P. Bodey. Fungal infection and fever of unknown origin in neutropenic patients, Am. J. Med. 80, 112-119 (1986).
9. M. D. Meyer, Current role of therapy with amphotericin B. Clin. Infect. Dis. 14, s154-160 (1992).
10. http://chem.sis.nlm.nih.gov/aidsdrg4.html
11. J. Bolard, How do the polyene macrolide antibiotics affect the cellular membrane properties?, Biochim. Biophys. Acta 864, 257-304 (1986).
12. N. H. Georgopapdakou and T. J. Walsh, Antifungal Agents: Chemotherapeutic Targets and Immunologic Strategies, Antimicrob. Agents Chemother. 40, 279-91 (1996).
13. J. Brajtburg, W. G. Powderly, G. S. Kobayashi and G. Medoff, Current understanding of mechanisms of action, Antimicrob. Agents Chemother. 34, 183-8 (1990).
14. D. W. Warnock, Amphotericin B: an introduction, J. Antimicrob. Chemother. 28, 27-38 (1991).
15. G. G. Chabot, R. Pazdur, F. A. Valeriote and L. H. Baker, Pharmocokinetics and toxicity of continuous infusion of amphotericin B in cancer patients. J. Pharm. Sci. 78, 307-10 (1989).
16. J. P. Tolins and L. Raij, Adverse effect of amphotericin B administration on renal hemodynamics in the rat: neurohumoral mechanisms and influence of calcium channel blocker. J. Pharmacol. Exp. Ther. 245, 594-9 (1988).
17. M. L. Gardner, P. Godley and S.M. Wasan, Sodium loading treatment of amphotericin B-induced nephrotoxicity. DICP 24, 940-5 (1990).
18. R. R. New, M. L. Chance and S. Heath, Antileishmanial activity of amphotericin and other antifungal agents entrapped in liposomes, J. Antimicrob. Chemother. 8, 371-81 (1981).
19. J. R. Graybill, P.C. Craven, R. L. Taylor, D. M. Williams and W. E. Magee, Treatment of murine cryptococcosis with liposome-associated amphotericin B, J. Infect. Dis. 145, 748-52 (1982).
20. G. Lopez-Berestein, R. Mehta, R. L. Hopfer, K. Mills, L. Kasi, K. Mehta, V. Fainstein, M. Luna, E. M. Hersh and R.L. Juliano, Treatment and prophylaxis of disseminated infection due to Candida albicans in mice with liposome-encapsulated amphotericin B, J. Infect. Dis. 147, 939-45 (1983).
21. G. Lopez-Berestein, R. L. Hopfer, R. Mehta, K. Mehta, E. M. Hersh and R. L. Juliano, Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B. Antimicrob. Agents Chemother. 25, 366-77 (1984).
22. R. L. Hopfer, K. Mills, R. Mehta, G. Lopez-Berestein, V. Fainstein and R. L. Juliano, In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B. Antimicrob. Agents Chemother. 25, 387-9 (1984).
23. R. Mehta , G. Lopez-Berestein, R. Hopfer, K. Mills and R. L. Juliano, Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells, Biochim Biophys. Acta 770, 230-4 (1984).
24. G. Lopez-Berestein, M. G. Rosenblum and R. Mehta, Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans, Cancer Drug Delivery 1, 199-205 (1984).
25. G. Lopez-Berestein, R. L. Hopfer, R. Mehta, K. Mehta, E. M. Hersh and R. L. Juliano, Liposome-encapsulated amphotericin B for treatment of disseminated candidiasis in neutropenic mice, J. Infect. Dis. 150, 278-83 (1984).
26. G. Lopez-Berestein, T. McQueen and K. Mehta, Protective effect of liposomal-amphotericin B against C. albicans infections in mice, Cancer Drug Delivery 2, 183-9 (1985).
27. G. Lopez-Berestein, V. Fainstein, R. Hopfer, K. Mehta, M. P. Sullivan, M. Keating, M.G. Rosenblum, R. Mehta, M. Luna, E. M. Hersh et al., Liposomal amphotericin B for the treatment of fungal infections in patients with cancer: a preliminary study, J. Infect. Dis. 151, 704-10 (1985).
28. V. J. Wiebe and M. W. De Gregorio, Liposome encapsulated amphotericin B: a promising new treatment for disseminated fungal infections, Rev. Infect. Dis. 10, 1097-101 (1988).
29. C. Tremblay, M. Barza, C. Fiore and F. Szoka, Efficacy of liposome-intercalated amphotericin B in the treatment of systemic candidasis in mice, Antimicrob. Agents Chemother. 26,170-3 (1984).
30. C. Tremblay, M. Barza, F. Szoka, M. Lahav and J. Baum, Reduced toxicity of liposome-associated amphotericin B injected intravitreally in rabbits, Invest. Opthal. Vis. Sci. 26, 711-8 (1985).
31. R. L. Taylor, D. M. Williams, P. C. Craven, J. R. Graybill, D. J. Drutz and W. E. Magee, Amphotericin B in liposomes: novel therapy of histoplasmosis, Am. Rev. Respir. Dis. 125, 610-16 (1982).
32. J. D. Berman, W. L. Hanson, W. L. Chapman, C. R. Alving and G. Lopez-Berestein, Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys, Antimicrobial. Agents Chemother. 30, 847-51 (1986).
33. C. B. Ponosian, M. Barza, F. Szoka and D. J. Wyler, Treatment of experimental cutaneous leishmaniasis with liposome-intercalated amphotericin B. Antimicrob. Agents Chemother. 25, 655-56 (1984).
34. S. L. Croft, R. N. Davidson and E. A. Thornton, Liposomal amphotericin B in the treatment of visceral leishmaniasis, J. Antimicrob. Chemother. 28, 111-8 (1991).
35. L. Gradoni, R. N. Davidson, S. Orsini and P. Betto, Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice, J. Drug Targeting 1, 311-6 (1993).
36. G. Lopez-Berestein, G. P. Bodey, L. S. Frankel and K. Mehta, Treatment of hepatosplenic candidiasis with liposomal-amphotericin B, J. Clin. Oncol. 5, 310-7 (1987).
37. G. Lopez-Berestein, G. P. Bodey, V. Fainstein, M. Keating, L. S. Frankel, B. Zeluff, L. Gentry and K. Mehta, Treatment of systemic fungal infections with liposomal amphotericin B, Arch. Intern. Med. 149, 2533-8 (1989).
38. J. Torre-Cisneros, J. L. Villanueva, J. M. Kindelan, R. Jurado and P. Sanchez-Guijo, Successful treatment of antimony-resistant visceral leishmaniasis with liposomal amphotericin B in patients infected with human immunodeficiency virus, Clin. Infect. Dis. 17, 625-7 (1993).
39. T. Fusai, R. Durand, Y. Boulard, M. Paul, C. Bories, D. Rivollet, R. Houin and M. Deniau, Importance of drug carriers in the treatment of visceral leishmaniasis, Medecine Tropicale 55, 73-8 (1995).
40. P. Linden, P. Williams and K. M. Chan, Efficacy and safety of amphotericin B lipid complex injection (ABLC) in solid-organ transplant recipients with invasive fungal infections, Clin. Transplant. 14(4 Pt 1), 329-39 (2000).
41. A. Adedoyin, C. E. Swenson, L. E. Bolcsak, A. Hellmann, D. Radowska, G. Horwith, A. S. Janoff and R. A. Branch, A pharmacokinetic study of amphotericin B lipid complex injection (Abelcet) in patients with definite or probable systemic fungal infections, Antimicrob. Agents Chemother. 44(10), 2900-2 (2000).
42. 99mTc-labeled liposomes in patients with cancer, Cancer Res. 44, 375-8 (1984).
43. 99mTc-labeled multilamellar liposomes in rats and mice, Int. J. Nucl. Med. Biol. 11, 35-7 (1984).
44. R. Perez-Soler, G. Lopez-Berestein, L. Kasi, F. Cabanillas, M. Jahns, H. Glenn, E. M. Hersh and T. Haynie, Distribution of technetium-99m-labeled multilamellar liposomes in patients with Hodgkin's disease, J. Nucl. Med. 26, 743-7 (1985).
45. R. T. Mehta, T. J. McQueen, A. Keyhani and G. Lopez-Berestein. Phagocyte transport as mechanism for enhanced therapeutic activity of liposomal amphotericin B. Exp. Chemother. 40, 256-2 (1994).
46. K. M. Wasan, K. Vadiei, G. Lopez-Berestein and D. R. Luke. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats, J. Infect. Dis. 161, 562-6 (1990).
47. A. J. Atkinson and J. E. Bennett, Amphotericin B pharmacokinetics in humans, Antimicrobial. Agents Chemother. 13, 271-8 (1978).
48. R. N. Davidson, L. Di Martino, L. Gradoni, R. Giacchino, R. Russo, G. B. Gaeta, R. Pempinello, S. Scott, F. Raimondi, A. Cascio et al., Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial , Quart. J. Med. 87, 75-81 (1994).
49. G. Lopez-Berestein, Liposomes as carriers of antifungal drugs. Annals of the New York Academy of Sciences 544, 590-7 (1988).
50. K. M. Wasan and G. Lopez-Berestein, Targeted liposomes in fungi: modifying the therapeutic index of amphotercin B by its incorporation into negatively charged liposomes, J. Liposome Res. 5, 883-903 (1995).
51. J. Brajtburg, S. Elberg, J. Bolard and G. Medoff, Interaction of plasma proteins and lipoproteins with amphotericin B, J. Infect. Dis.149, 986-992 (1984).
52. T. E. Andreoli, The anatomy of amphotericin B-cholesterol pores in lipid bilayer membranes, Kidney Int. 4, 337-345 (1973).
53. M. H. Koldin, G. S. Kobayashi, J. Brajtburg and G. Medoff, Effects of elevation of serum cholesterol and administration of amphotericin B complexed to lipoproteins on amphotericin B-induced toxicity to rabbits, Antimicrobial. Agents Chemother. 28, 144-5 (1985).
54. K. J. Christansen, E. M. Bernard, J. W. M. Gold and D. Armstrong, Distribution and activity of amphotericin B in humans, J. Infect. Dis. 152, 762-5 (1985).
55. K. M. Wasan, G. A. Brazeau, A. Keyhani, A. C. Hayman and G. Lopez-Berestein, Role of liposome composition and temperature on the distribution of amphotericin B in serum lipoproteins, Antimicrobial. Agents Chemother. 37, 246-250 (1993).
56. A. L. Kennedy and K. M. Wasan, Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content, J. Pharm. Sci. 88, 1149-55 (1999).
57. J. Babiak and L. L. Rudel, Lipoproteins and atherosclerosis, Bailliere's Clin. Endocrinol. Metab. 1, 515-21 (1987).
58. R. J. Cushley, W. D. Treleaven, Y. I. Parmar, R. S. Chana and D. B. Fenske, Surface diffusion in human serum lipoproteins, Biochem. Biophys. Res. Commun. 146, 1139-45 (1987).
59. W. K. Surewicz, R. M. Epand, H. J. Pownall and S. W. Hui, Human apolipoprotein A-I forms thermally stable complexes with anionic but not with zwitterionic phospholipids, J. Biol. Chem. 261, 16191-7 (1986).
60. R. L. Juliano, C. W. M. Grant, K. R. Barber and M. A. Kalp, Mechanism of the selective toxicity of amphotericin B incorporated into liposomes, Mol. Pharmacol. 31, 1-11 (1987).
61. A. S. Janoff, L. T. Boni, M. C. Popescu, S. R Minchey, P. R. Cullis, T. D. Madden, T. Taraschi, S. M. Gruner, E. Shyamsunder, M. W. Tate et al., Unusual lipid structures selective reduce the toxicity of amphotericin B, Proc. Natl. Acad. Sci. U.S.A. 85, 6122-6 (1988).
62. W. R. Perkins, S. R. Minchey, L. T. Boni LT, C. E. Swenson, M. C. Popescu, R. F. Pasternack and A. S. Janoff, Amphotericin B-phospholipid interactions responsible for reduced mammalian cell toxicity, Biochim. Biophys. Acta. 1107, 271-2 (1992).
63. H. J. Krause and R. L. Juliano, Interactions liposome-incorporated amphotericin B with kidney epithelial cells, Mol. Pharmacol. 34, 286-97 (1988).
64. V. Joly, S. J. Line, C. Carbon and P. Yeni, Interactions of free and liposomal amphotericin B with renal proximal tubular cells in primary culture, J. Pharmacol. Exp. Ther. 255, 17-22 (1990).
65. J. Brajtburg, S. Elberg, G. S. Kobayashi and G. Medoff, Effects of serum lipoproteins on damage to erythrocytes and Candida albicans cells by polyene antibiotics, J. Infect. Dis. 153, 623-6 (1986).
66. J. Barwicz, R. Gareau, A. Audet, A. Morisset, J. Villiard and I. Gruda, Inhibtion of the interaction between lipoproteins and amphotericin B by some delivery systems, Biochem. Biophys. Res. Commun. 181, 722-6 (1991).
67. K. M. Wasan, M. G. Rosenblum, L. Cheung and G. Lopez-Berestein, Influence of lipoproteins on renal cytotoxicity and antifungal activity of amphotericin B, Antimicrob. Agents Chemother. 38, 223-7 (1994).
68. K. M. Wasan and J. S. Conklin, Enhanced Amphotericin B Nephrotoxicity in Intensive Care Patients with elevated low-density lipoprotein cholesterol, Clin. Infect. Dis. 24, 78-80 (1997).
69. S. Jullien, A. J. Vertut-Croquin, J. Brajtburg and J. Bolard, Circular dichroism for the determination of amphotericin B binding to liposomes, Anal. Biochem. 1972, 197-202 (1998).
70. J. Bolard, J. Legrand, F. Heitz and B. Cybulska, One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self association in the medium, Biochem. 30, 5707-15 (1991).
71. S. Jullien, J. Brajtburg and J. Bolard, Affinity of amphotericin B for phosphatidylcholine vesicles as a determinant of the in vitro cellular toxicity of liposomal preparations, Biochim. Biophys. Acta 1021, 39-45 (1990).
72. K. M. Wasan and J. S. Conklin, Evaluation of renal toxicity and antifungal activity of free and liposomal amphotericin B following a single intravenous dose to diabetic rats with systemic candidasis, Antimicrob. Agents Chemother. 40, 1806-10 (1996).
73. K. M. Wasan, V. B. Grossie Jr. and G. Lopez-Berestein, Effects of Intralipid infusion on rat serum lipoproteins, Lab Animals 28, 138-142 (1994).
74. K. M. Wasan, V. B. Grossie Jr. and G. Lopez-Berestein, Concentrations in serum and tissue distribution of free and liposomal amphotericin B in rats on continuous Intralipid infusion, Antimicrob. Agents Chemother. 38, 2224-6 (1994).
75. K. M. Wasan, A. L. Kennedy, S. M. Cassidy, M. Ramaswamy, L. Holtorf, J. W. Chou and P. H. Pritchard, Pharmacokinetics, distribution in serum lipoproteins and tissues, and renal toxicities of amphotericin B and amphotericin B lipid complex in a hypercholesterolemic rabbit model: single-dose studies, Antimicrob. Agents Chemother. 42, 3146-52 (1998).
76. M. Ramaswamy, K. D. Peteherych, A. L. Kennedy and K. M. Wasan, Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities, Antimicrob. Agents Chemother. 45, 1184-91 (2001)
77. S. M. Palmer, R. H. Drew, J. D. Whitehouse, V. F. Tapson, R. D. Davis, R. R. McConnell, S. S. Kanj and J. R. Perfect, Safety of aerosolized amphotericin B lipid complex in lung transplant recipients, Transplantation 72, 545-8 (2001).
78. D. C. Knoppert, H. E. Salama and D. S. Lee, Eradication of severe neonatal systemic candidiasis with amphotericin B lipid complex, Ann. Pharmacother. 35, 1032-6 (2001).
79. R. Herbrecht, A. Avurignon, E. Andres, R. Guillemain, A. Suc, D. Eyer, C. Pailler, V. Letscher-Bru, G. Levenger and G. Schaison, Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients, Eur. J. Clin. Microbiol. Infect. Dis. 20, 77-82 (2001).
80. D. Goldblum, B. E. Frueh, S. Zimmerli and M. Bohnke, Treatment of postkeratitis fusarium endophthalmitis with amphotericin B lipid complex, Cornea 19, 853-6 (2000).
81. P. P. Cook, Amphotericin B lipid complex for the treatment of recurrent blastomycosis of the brain in a patient previously treated with itraconazole, South Med. J. 94, 548-9 (2001).
82. D. D. Lasic, Mixed micelles in drug delivery, Nature 355, 279-80 (1992).
83. C. Gates and R. J. Pinney, Amphotericin B and its delivery by liposomal and lipid formulations, J. Clin. Pharmacy Ther. 18, 147-53 (1993).
84. S. W. Sanders, K. N. Buchi, M. S. Goddard, J. K. Lang and K. G. Tolman, Single-dose pharmacokinetics and tolerance of cholesterol sulphate complex of amphotericin B administered to healthy volunteers, Antimicrob. Agents Chemother. 35:1029-34 (1991).
85. R. Chopra, S. Blair, J. Strang, P. Cervi, K. G. Patterson and A. H. Goldstone, Liposomal Amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients, J. Antimicrob. Agents 28, 93-104 (1991).
86. O. Ringden, F. Meunier, J. Tollemar, P. Ricci, S. Tura, E. Kuse, M. A. Viviani, N. C. Gorin, J. Klastersky and P. Fenaux et al., Efficacy of amphotericin B (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients, J. Antimicrob Agents 28, 73-82 (1991).
87. F. Meunier, H. G. Prentice and O. Ringden, Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial, J. Antimicrob. Agents 28, 83-91 (1991).
88. R. V. Fleming, H. M. Kantarjian, R. Husni, K. Rolston, J. Lim, I. Raad, S. Pierce, J. Cortes and E. Estey, Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia, Leuk Lymphoma 40, 511-20 (2001).
89. H. R. Pace and S. I. Schantz, Nystatin (Mycostatin) in the treatment of monilial and nonmonilial vaginitis, JAMA 162, 268-71 (1956).
90. J. E. Stark, Allergic pulmonary aspergillosis successfully treated with inhalations of nystatin, Dis. Chest. 51, 96-9 (1967).
91. V.D. Newcomer, E. T. Wright, T. H. Sternberg, J. H. Graham, R. H. Wier, R. O. Egebery, Evaluation of Nystatin in the treatment of coccidioimycosis in man, in "Therapy of Fungal Disease" (T. H. Sternberg and V. D. Newcomer, ed.), p. 260-7. Little Brown, Boston, 1955.
92. M. C. Broughton, M. Bard and N. D. Lees, Polyene resistance ergosterol producing strains of Candida albicans, Mycoses 34, 75-83 (1991).
93. R. T. Mehta, R. L. Hopfer, L. A. Gunner, R. L. Juliano and G. Lopez-Berestein, Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis, Antimicrob. Agents Chemother. 31, 1897-900 (1987).
94. R. T. Mehta, R. L. Hopfer, T. McQueen, R. L. Juliano and G. Lopez-Berestein,Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections, Antimicrob. Agents Chemother. 31, 1901-3 (1987).
95. T. L. Wallace, B. Paetznick, P. A. Cossum, G. Lopez-Berestain, J. H. Rex and E. Anaissie, Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice, Antimicrob. Agents Chemother. 41, 2238-43 (1997).
96. A. H. Groll, C. E. Gonzalez, N. Giri, K. Kligys, W. Love, J. Peter, E. Feuerstein, J. Bacher, S. C. Piscitelli and T. J. Walsh, Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics. J. Antimicrob. Chemother. 43, 95-103 (1999).
97. A. H. Groll, V. Petraitis, R. Petraitiene, A. Field-Ridley, M. Calendario, J. Bacher, S. C. Pliscitelli and T. J. Walsh, Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits, Antimicrob. Agents Chemother. 43, 2453-7 (1999).
98. A. H. Groll, D. Mickiene, K. Werner, R. Petraitiene, V. Petraitis, M. Calendario, A. Field-Ridley, J. Crisp, S. C. Piscitelli and T. J. Walsh, Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits, Antimicrob. Agents Chemother. 44, 950-7 (2000).
99. K. L. Oakley, C. B. Moore and D. W. Denning, Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole, Antimicrob. Agents Chemother 43, 1264-6 (1999).
100. D. W. Denning and P. Warn, Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporarily neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B, Antimicrob. Agents Chemother. 43, 2592-9 (1999).
101. A. J. Carrillo-Munoz, G. Quindos, C. Tur, M. T. Ruesga, Y. Miranda, O. Delvalle, P. A. Cossum and Wallace, In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole, J. Antimicrob. Chemother. 44, 397-491 (1999).
102. M. Ramaswamy, T. L. Wallace, P. A. Cossum and K. M. Wasan, Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog, and rat plasma, Antimicrob. Agents Chemother. 43, 1424-8 (1999)
103. S. M. Cassidy, F. W. Strobel and K. M. Wasan, Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins, Antimicrob. Agents Chemother. 42, 1878-88 (1998).
104. A. Rios, M. Rosenblum, G. Crofoot, R. P. Lenk, A. Hayman and G. Lopez-Berestein, Pharmacokinetics of liposomal nystatin in patients with human immunodeficiency virus infection, J. Infect. Dis. 168, 253-4 (1993).
105. Y. Krupova, M. Mistrik, E. Bojtarova, D. Sejnova, I. Ilavska, V. Krcmery Jr., Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients, Support Care Cancer 9, 209-210 (2001).
106. R. T. Mehta, T. J. McQueen, A. Keyhani and G. Lopez-Berestein, Liposomal hamycin: reduced toxicity and improved antifungal efficacy in vitro and in vivo, J. Infect. Dis. 164, 1003-6 (1991).
107. M. Moonis, I Ahmad and B. K. Bachhawat, Liposomal hamycin in the control of experimental aspergillosis in mice: relative toxicity, therapeutic efficacy and tissue distribution of free and liposomal hamycin, Indian J. Biochem. Biophys. 29, 339-45 (1992).
108. M. Moonis, I. Ahmad and B. K. Bachhawat, Mannosylated liposomes as carriers for hamycin in the treatment of experimental aspergillosis in Balb/C mice, J. Drug Targeting 1, 147-55 (1993).
109. J. Harindran, K. K. Chakraborty and S. R. Naik, Preparation, relative toxicity and therapeutic efficacy in mice and rats of liposomal HA-1-92, a new oxohexaene polyene macrolide antibiotic, J. Pharm. Pharmacol. 51, 771-6 (1999).